title: [Clinical evaluation of serum CA130 in patients with lung cancer].
abstract: CA130 is a glycoprotein which is recognized by monoclonal antibodies-(130-22 and 145-9) produced by immunization with human lung adenocarcinoma cell line (PC-9). CA130 is considered to be a new tumor marker, different from CA125, since it has a separate antigenic determinant. We used the D-7111 kit (Daiichi Radioisotope Laboratories, Ltd.) to measure the serum level of CA130 in 290 patients with lung cancer, 171 patients with noncancerous lung disease (N-CLD) and 93 healthy adults. In addition, CEA, CA19-9, CA125 and sialyl SSEA-1 antigen (SLX) were also measured for the same serum samples when possible. The cutoff level for CA130 was 35 U/ml. The overall positive rates for CA130 were 32% in the lung cancer patients, 23% in the N-CLD patients and 0% in the healthy adults. The positive rate in the lung cancer patients was significantly higher than in the N-CLD patients (p less than 0.05). As a function of the histological type of lung cancer, the positive rates for CA130 were 44% in 120 patients with adenocarcinoma, 17% in 115 patients with squamous cell carcinoma, 33% in 36 patients with small cell carcinoma, 42% in 12 patients with large cell carcinoma and 29% in 7 patients with miscellaneous cell type. The positive rate in the patients with adenocarcinoma was significantly higher than in the patients with squamous cell carcinoma (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: Y
authors.initials: Y
authors.lastname: Matsubara
authors.forename: T
authors.initials: T
authors.lastname: Shiota
authors.forename: H
authors.initials: H
authors.lastname: Ishida
authors.forename: T
authors.initials: T
authors.lastname: Hanawa
authors.forename: K
authors.initials: K
authors.lastname: Yagi
authors.forename: S
authors.initials: S
authors.lastname: Kosaba
authors.forename: R
authors.initials: R
authors.lastname: Hatakenaka
authors.forename: T
authors.initials: T
authors.lastname: Funatsu
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000276:immunology; D006017:Glycolipids / Q000032:analysis; D006801:Humans; D016256:Lewis X Antigen; D008175:Lung Neoplasms / Q000276:immunology*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006017:Glycolipids; D016256:Lewis X Antigen